Hoya’s Reports Strong IOL Sales in Fiscal 2017 Fourth Quarter

May 12, 2017: By Jon Swedien

Hoya logoHoya’s intraocular lens (IOL) sales were strong during its fiscal 2017 fourth quarter—Jan. 1 to March 31, 2017, according to the Japanese company.

The firm announced May 11 that its IOL sales for cataracts continued to perform well in Japan, after being introduced in the previous fiscal year. Outside of Japan, IOL sales grew, outpacing performance for the same period in the prior fiscal year “by a significant margin,” Hoya said.

Hoya’s Life Care business segment, which includes eyeglass lenses, contact lenses, and intraocular lenses (IOLs), plus other products, saw an increase in revenues of 3.5 percent, with sales totaling 83,752 million yen (US $739 million, as of May 12, 2017) in the quarter.

Hoya reported that its overall revenues increased 3.8 percent to 126,304 million yen (US $1.12 billion) in the company’s 2017 fiscal fourth quarter.

Revenues for the fiscal year ended March 31, 2017, totaled 478,927 million yen (US $4.23 billion), down 5.3 percent year over year.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022